Expression profiling of glial genes during Drosophila embryogenesis  by Altenhein, Benjamin et al.
Developmental Biology 296 (2006) 545–560
www.elsevier.com/locate/ydbioGenomes & Developmental Control
Expression profiling of glial genes during Drosophila embryogenesis
Benjamin Altenhein a,1, Angela Becker a,1, Christian Busold b, Boris Beckmann b,
Jörg D. Hoheisel b, Gerhard M. Technau a,⁎
a Institute of Genetics, University of Mainz, Germany
b Division of Functional Genome Analysis, Deutsches Krebsforschungszentrum Heidelberg, Germany
Received for publication 22 March 2006; revised 19 April 2006; accepted 21 April 2006
Available online 5 May 2006Abstract
In the central nervous system of Drosophila, the induction of the glial cell fate is dependent on the transcription factor glial cells missing (gcm).
Though a considerable number of other genes have been shown to be expressed in all or in subsets of glial cells, the course of glial cell
differentiation and subtype specification is only poorly understood. This prompted us to design a whole genome microarray approach comparing
gcm gain-of-function and, for the first time, gcm loss-of-function genetics to wildtype in time course experiments along embryogenesis. The
microarray data were analyzed with special emphasis on the temporal profile of differential regulation. A comparison of both experiments enabled
us to identify more than 300 potential gcm target genes. Validation by in situ hybridization revealed expression in glial cells, macrophages, and
tendon cells (all three cell types depend on gcm) for 70 genes, of which more than 50 had been unknown to be under gcm control. Eighteen genes
are exclusively expressed in glial cells, and their dependence on gcm was confirmed in situ. Initial considerations regarding the role of the newly
discovered glial genes are discussed based on gene ontology and the temporal profile and subtype specificity of their expression. This collection of
glial genes provides an important basis for the clarification of the genetic network controlling various aspects of glial development and function.
© 2006 Elsevier Inc. All rights reserved.Keywords: Glial development; gcm; Glial genes; Microarrays; Drosophila embryogenesisIntroduction
The central and peripheral nervous systems (CNS and PNS)
comprise two major cell types: neurons, which receive, transmit
and integrate information, and glial cells that ensheath the
neurons and their axons and fulfil several accessory functions. In
both vertebrates and invertebrates, these two cell types are
derived from multipotent neural stem cells. In Drosophila,
neural stem cells delaminate from the neurogenic ectoderm in a
stereotypic spatial and temporal pattern. Each of these stem cells
can be addressed by its subectodermal position and specific gene
expression (Doe, 1992; Urbach and Technau, 2003) as well as by
its characteristic cell lineage (Bossing et al., 1996; Schmidt et al.,
1997). According to their progeny, these cells can be divided into
neuroblasts (NB) that give rise only to neurons, neuroglioblasts⁎ Corresponding author. Fax: +49 6131 392 4584.
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(GB) that produce only glia. The decision to acquire particular
neuronal or glial cell fates needs precise regulation in order to
generate a functional nervous system. In Drosophila, the glial
cell fate is induced by the transcription factor glial cells
missing/glial cells deficient (gcm/glide) (Hosoya et al., 1995;
Jones et al., 1995; Vincent et al., 1996). gcm is transiently
expressed in all embryonic glial cells, except for the
mesectoderm-derived midline glia. A second gcm gene,
gcm2, is also expressed in all lateral glial cells, but much
weaker than gcm itself (Kammerer and Giangrande, 2001).
Both paralogs form a gene complex with shared enhancer
elements (Kammerer and Giangrande, 2001; Ragone et al.,
2003; Jones et al., 2004; Jones, 2005). The key role for gcm in
glial cell development is underlined by the fact that gcm mutant
embryos lack nearly all lateral glial cells, whereas ectopically
expressed gcm transforms presumptive neurons into glial cells
(Hosoya et al., 1995; Jones et al., 1995; Vincent et al., 1996;
Akiyama-Oda et al., 1998). Like gcm, gcm2 promotes the glial
fate upon ectopic expression, but gcm2 loss-of-function has
546 B. Altenhein et al. / Developmental Biology 296 (2006) 545–560only a mild effect on glial cells (Kammerer and Giangrande,
2001).
Beside their role in early glial cell development, recent stu-
dies demonstrated a role forgcm as well as gcm2 in both glial and
neuronal differentiation in the optic lobes of third instar larval
stages (Chotard et al., 2005). Hence, the mode of neuronal or
glial downstream target gene activation by Gcm appears to be
context-dependent. Furthermore, both genes are expressed in
cells of the hematopoietic anlage, the prohemocytes, and induce
the differentiation into plasmatocytes and finally into macro-
phages (Bernardoni et al., 1997; Alfonso and Jones, 2002;
Bataille et al., 2005).
To shed light on the regulation of gliogenesis, the promoter
region of gcm was subject to intense studies. Transcriptional
regulation of gcm as the nodal point of gliogenesis in the
embryo is achieved by multi-component upstream pathways
(reviewed in Jones, 2005), as well as auto- and cross-regulation
with gcm2 (Miller et al., 1998; Kammerer and Giangrande,
2001; Jones et al., 2004). Because of the transient expression of
gcm, it is necessary to activate glial-specific genes, which
accomplish the differentiation and maintenance of the glial cell
fate. To date, only a few downstream target genes of Gcm have
been well characterized, like reversed polarity (repo), pointed
(pnt), and tramtrack (ttk), which are all expressed in lateral glial
cells (Klämbt, 1993; Klaes et al., 1994; Xiong et al., 1994;
Halter et al., 1995; Giesen et al., 1997). The homeodomain
protein Repo cooperates with Pnt to promote the glial fate, as
well as with Ttk to suppress the neuronal fate (Badenhorst et al.,
2002; Yuasa et al., 2003). Synergistic cooperations between the
transcription factors Gcm, Repo, Pnt and Ttk seem to be an
additional way to activate glial-specific genes, like the
expression of locomotion defects (loco) (Granderath et al.,
1999, 2000). Both repo and loco are exclusively expressed in all
lateral glial cells, while pnt and ttk are also expressed in neurons
and/or the Gcm-independent midline glia. Many other genes,
which have been described to be expressed in lateral glial cells,
are expressed in subsets of these cells only. The composition of
these subsets varies in number and identity of the cells and does
not necessarily reflect the classification of glial subtypes as
introduced by Ito et al. (1995). This classification is based on
the position and the morphology of the cells in the embryonic
CNS. Whether a developmental program underlying this
subtype specification exists has not been shown so far. The
clarification of the processes underlying the determination and
differentiation of glial subtypes and their specific functions in
the developing and mature nervous system requires the
identification of the genetic network acting downstream of or
in cooperation with the master regulator Gcm.
Recently, two screens for genes acting downstream of gcm
have been published, which took advantage of the microarray
technique to compare gene expression in wildtype embryos ver-
sus embryos overexpressing gcm throughout the CNS (Egger et
al., 2002; Freeman et al., 2003). Using an in silico approach and
a public database search in addition to the microarray approach,
Freeman et al. (2003) identified about 40 new glial genes. Ne-
vertheless, there was only a minor overlap of candidate genes
uncovered by the three approaches of Freeman et al. as well asbetween the twomicroarray screens (Egger et al., 2002; Freeman
et al., 2003). This prompted us to design a new-microarray-
based screen for further gcm target genes. We used a whole-
genome microarray approach that compares ectopic expression
of gcm to wildtype and, for the first time, gcm loss-of-function to
the wildtype situation. To ectopically express gcm, we used a
Gal4 driver line, which is exclusively expressed in the CNS at
the same time as the endogenous gcm. The loss-of-function ex-
periment was achieved by sorting staged, living gcm mutant
embryos by means of different green fluorescent protein (GFP)
carrying balancer chromosomes and an embryo sorter (Furlong
et al., 2001b). To identify the dynamic changes in gene expres-
sion, we generated a time course experiment throughout em-
bryogenesis. This antagonistic approach in combination with
time course gene expression profiling, various quality controls
and carefully selected filtering methods enabled us to identify
about 70 novel gcm target genes, 18 of which exclusively ex-
pressed in glial cells.
Materials and methods
Fly strains
Mz1060-Gal4, UAS-gcm (Bloomington stock B-#5446), gcmN7-4 (Bloo-
mington stock B-#4104) (Vincent et al., 1996), Kr-GFP (Bloomington stock B-
#5194) and Ubi-GFP (Bloomington stock B-#4888) balancer chromosomes
(Casso et al., 1999, 2000), wildtype Oregon R.
Embryo collection
Eggs were collected for 1 h at 25°C on standard apple juice plates and shifted
to either 18°C, 25°C or 29°C for further development. Embryos were
dechorionated using 7.5% hypochlorite, washed in water and either fixed for
antibody staining, snap-frozen in liquid nitrogen for RNA preparation or
transferred to PBT (PBS, 3% Tween-20) and GFP-sorted.
Antibody staining
For each embryo collection, a small fraction was fixed as described
(Patel, 1994) and stained for the glial marker protein Repo using a rabbit
anti-Repo antibody (Halter et al., 1995) and alkaline-phosphatase-conjugated
donkey anti-rabbit secondary antibodies. In situ hybridizations were counter-
stained with rabbit anti-Repo antibodies and biotin-conjugated secondary
antibodies (Dianova, Hamburg, Germany). Immunolabelings were performed
with rabbit anti-Repo and rat anti-Elav antibodies (7E8A10, DSHB Iowa,
USA) and donkey anti-rabbit/anti-mouse secondary antibodies conjugated
with Fitc/Cy5 respectively (Dianova, Hamburg, Germany). Embryos were
staged according to standard morphological markers (Campos-Ortega and
Hartenstein, 1997).
Sorting
gcmN7-4 mutant flies were balanced with either Kr-GFP (for stages 10 to 13)
or Ubi-GFP (for stages 14 to 16) balancer chromosomes. Eggs were collected as
described above, transferred into PBT buffer according to Furlong et al. (2001b)
and homozygous mutant embryos were automatically sorted with the Copas™
Select embryo sorter (Union Biometrica, Somerville, MA, USA) by their lack of
GFP expression. The two different balancer chromosomes used showed
different characteristics concerning the ability to distinguish between ho-
mozygous and heterozygous embryos at different stages. In Fig. 1, two
examples of the Copas™ sorter plots are given. An aliquot of sorted embryos
was fixed for antibody staining as described above, and the major portion was
snap-frozen in liquid nitrogen.
Fig. 1. Sorting of homozygous mutant embryos. (A, B) Two different GFP balancer chromosomes were used to balance the gcmN7-4 mutation. Kr-GFP (A) was used to
balance and sort stages 10–12, Ubi-GFP (B) was used for stages 13–16. Sorter plots of the Copas™ embryo sorter (Union Biometrica, Somerville, USA) with green
fluorescent signal (FLU1) plotted against autofluorescence (FLU2) show the three populations of genotypes. The black rectangles indicate the sorted fraction which
lacks GFP signal.
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Total RNA was prepared from frozen embryos using the RNeasy® kit
followed by polyA+-RNA extraction with the Oligotex® kit (both Qiagen,
Hilden, Germany) according to manufacturer's instructions. One microgram of
polyA+-RNA was used for each labeling reaction. The quality of polyA+-RNA
preparations was checked by Northern blot and RT-PCR under standardized
conditions.
Microarrays
Microarrays were used (Heidelberg FlyArray) that contain PCR products of
21,306 Drosophila open reading frames together with 2502 controls, spotted in
two replicates on each array (∼48,000 spots per array) (Hild et al., 2003).
Sample preparation and microarray hybridization
An indirect labeling method was used to reverse-transcribe 1 μg of
denatured polyA+-RNA with 4.5 μg random primers and 0.75 μg oligo-dT
primers (both from Invitrogen, Karlsruhe, Germany). First-strand cDNA
synthesis, sample preparation and microarray hybridization were performed as
described in Hild et al. (2003).
Image analysis
Hybridized arrays were scanned directly after hybridization using the
GeneTac™ LS IV scanner (Perkin-Elmer Life Sciences, Wellesley, USA) and
the corresponding software. Fluorescent-labeled spotted controls on the arrays
were used to align laser intensities and photomultiplier settings for both
channels. Resulting images (16-bit gray-scale TIFF-format) for each channel
were loaded into the GenePix 5.0 software (Axon Instruments, Union City,
USA), and data were extracted as GenePix result files (gpr-format) for further
analysis.
Replicates
For each developmental stage examined in both experiments, at least four
independent replicates have been analyzed starting with independent egg
collections. All replicates include balanced dye swaps, except for stage 12 in the
GOF and stages 11 and 16 in the LOF, where only one dye swap was done. Only
arrays with a correlation coefficient above 0.8 were used for further analysis. For
every replicate, the developmental stage, the quality of the embryo collection and
the accuracy of the sorting were checked by antibody staining.Normalization, filtering and correspondence analysis
Statistical data analysis was performed with the Multi-Conditional
Hybridization Intensity Processing System (M-CHiPS) (Fellenberg et al.,
2002). Normalization was performed using linear regression normaliza-
tion with the M-CHiPS software package. Genes were filtered out when
their normalized median transcription intensities remained below a threshold of
10,000 pixels in all conditions and/or had a ratio to the control condition of less
than 1.5-fold. The significance of changes was assessed by a high stringent
criterion. ‘Min–max separation’ is calculated by taking the minimum distance
between all data points of two conditions (Beissbarth et al., 2000). Genes that
exhibited a min–max value of less than 0.0, 0.2 or 0.5 were discarded from
analysis in three subsequent filtering steps. Correspondence analysis (CA)
(Greenacre, 1984, 1993) is a clustering and projection method, which allows to
plot genes and hybridization conditions in the same space. In the resulting plot,
the displayed χ2 distance is a measure of association among genes and
hybridizations.
In situ hybridization
In vitro transcription and labeling of RNAwith Digoxygenin was performed
using the Dig-RNA labeling mix according to manufacturer's instructions
(Roche Diagnostics, Mannheim, Germany). Embryos from overnight collections
were dechorionated in 7.5% hypochlorite, fixed in PBS/heptane/formaldehyde
(35:50:15) and incubated for 1 h in hybridization buffer (50% formamide, 5×
SSC, 100 μg/ml ssDNA, 0.1% Tween-20). For fluorescent in situ hybridization,
embryos were treated with 0.1% sodium borohydrid solution in 0.1% PBT (PBS,
0.1% Tween-20) for 10 min to reduce the autofluorescent background.
Hybridization was performed overnight at 55°C using 10 μl of the Dig-labeled
RNA probe. The following procedure is described in Tautz and Pfeifle (1989);
Jiang et al. (1991); Kosman et al. (1991). For fluorescence detection of Dig-
labeled RNA probes, the TSA amplification Kit with either Cy3 or Cy5 (Perkin-
Elmer, Norwalk, CT) was used according to manufacturer's instructions.Results
Microarray analysis and quality control
Prior to array hybridization, we performed several tests
concerning the quality of the prepared RNA (Northern blot and
RT-PCR). Furthermore, different post-hybridization quality
controls were performed in order to define and reduce the
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reproducibility and reliability of our microarray data. We first
hybridized wildtype stage 10 mRNA labeled with Cy3 and Cy5
in three replicates to determine background noise within
identical samples. In order to compare differences in gene
expression between the wildtypic flies used for the ectopic
expression of gcm, we labeled RNA samples of stage 9 embryos
from Mz1060 with Cy3 and from UAS-gcm with Cy5 and vice
versa and hybridized these samples to microarrays. All control
arrays showed correlation coefficients between 0.98 and 0.99.
Data were normalized and filtered with the M-CHiPS software
package as described in the Materials and methods section. We
applied different filter criteria for both reproducibility and ratio
of normalized intensities and determined the number of genes
passing both criteria. A much higher number of differentially
expressed genes above 1.5-fold regulation were obtained when
Gal4 and UAS flies were compared than using identical wt
samples. Thus, differences in the genetic background of phe-
notypically wildtype fly strains lead to differences in expression
levels of certain genes and increase background noise. As a
consequence, embryos from both Gal4 and UAS line were
collected separately for control samples in the ectopic expression
experiment. RNA was extracted and then pooled in equal
amounts for sample labeling and hybridization. This mixed
‘wildtype control’ was not used for the analysis of homozygous
gcm mutant embryos. For this experiment, Oregon R wildtype
embryos were collected and treated as the sorted embryos. Both
control experiments were taken into consideration for the se-
lection of filter criteria in M-CHiPS. Hence, filtering data with a
differential regulation above 1.5-fold and a min–max separation
between 0.0 and 0.5 was chosen and applied to all microarray
data.
Ectopic expression of gcm and comparison with wildtype
It has been shown that ectopic expression of gcm in the
developing nervous system can induce the glial-specific tran-
scription factor Repo, which is generally used as a marker for all
lateral glial cells (Akiyama-Oda et al., 1998). Hence, ectopic
gcm is sufficient to induce the glial cell fate at the cost of
presumptive neurons. Conversely, ectopic expression of gcm in
epidermal cells leads to an activation of elav, a postmitotic
neuronal marker (Akiyama-Oda et al., 1998). These findings
prompted us to search for a Gal4 line which drives ectopic gcm
expression restricted to the nervous system (and not in the
ventral neuroectoderm which produces also epidermal cells) in a
time window similar to endogenous gcm expression. The Gal4
line Mz1060 fitted these criteria. This line shows Gal4
expression in nearly 60% of the cells in the ventral nerve cord,
beginning at stage 10, increasing to stage 13 and diminishing
until stage 15. In Fig. 2, the Repo/Elav pattern of both wildtype
embryos and embryos with ectopic expression of gcm (Mz1060::
gcm) in stages 12, 14, and 16 is shown.
To analyze the effect of this ectopic activation of gcm on
microarrays (gain-of-function, GOF), we collected embryos
from eight different time points (stage 9 to stage 16). Embryos
from each developmental stage were collected separately forMz1060::gcm as well as for both Mz1060 and UAS gcm flies as
‘wildtype control’. This was done in five separate experiments
starting from individual fly crosses and separate egg collections
for repeat experiments. Homogeneity of staging and effect of
ectopic activation of gcm were checked by anti-Repo antibody
stainings. RNAwas extracted, labeled and hybridized to micro-
arrays separately. Gene lists of differentially regulated genes
were created for all eight time points (Table 1 and Supplemen-
tary Table 1).
Sorting of homozygous gcm mutant embryos and comparison
with wildtype
In order to analyze differences in gene expression between
gcm mutant embryos (loss-of-function, LOF) and wildtype, we
made use of balancer chromosomes carrying the gene coding
for the green fluorescent protein (GFP) (Casso et al., 1999,
2000). We balanced the gcmN7-4 mutation (Vincent et al., 1996)
with either Kr-GFP or Ubi-GFP balancer chromosomes.
Homozygous mutant embryos can be detected unambiguously
by their lack of GFP expression. To circumvent the need for
RNA amplification, we used the Copas™ Select embryo sorter
(Union Biometrica, Somerville, MA, USA) for automated
sorting of living embryos as described in Furlong et al. (2001a,
b). Staged egg collections of gcmN7-4/GFP balanced parental
generation were sorted in up to six independent collections per
developmental stage examined, and homozygous mutant
embryos were kept. Wildtype (Oregon R) embryos were staged
and treated accordingly, without sorting for GFP. A fraction of
each sorting was fixed and stained with an antibody against the
glial marker Repo to check both staging and accuracy of the
sorting. Stages 10 to 14 and stage 16 were well staged, and the
sorting resulted in an accuracy of 98% homozygous mutant
embryos lacking Repo staining. Unfortunately, the stage 15 egg
collections turned out to be too heterogeneous with respect to
their developmental stage and, thus, were excluded from further
analysis. Two GFP balancer chromosomes were used for sorting
of stages 10 to 12 (Kr-GFP) and 13 to 16 (Ubi-GFP), res-
pectively, because the discrimination between the three popu-
lations of embryos (homozygous gcm mutant embryos without
GFP, heterozygous embryos and homozygous GFP balancer
carrying embryos) was easier with Kr-GFP in younger stages
and with Ubi-GFP in older stages (see Fig. 1). Microarray data
were generated using the same filter criteria as for the ectopic
expression (GOF experiment), and gene lists for six deve-
lopmental stages were generated (Table 1 and Supplementary
Table 2).
Processing of microarray data
Filtering for differential expression for every single time
point provided us with gene lists of up to several hundred
differentially regulated genes. These lists contain log2-
transformed values below the aspired threshold of 1.5-fold
differential regulation (see Supplementary Tables 1 and 2).
This accounts for the fact that in M-CHiPS genes pass the fold
regulation filter if at least one of the measurements in all
Fig. 2. Confocal images of the central nervous system of wt (A–C) and
Mz1060::gcm (D–F) embryos stained against the glial protein Repo (green) and
the postmitotic neuronal marker protein Elav (magenta). An excess of glial cells
at the expense of neurons upon ectopic expression of gcm compared to wildtype
is already detectable at stage 12 (A, D) and increases further until stage 14
(B, E). Ectopic glial cells are evenly distributed throughout the entire nervous
system at stage 16 (C, F).
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resulting value, though, is the median ratio of all replicates. We
combined the single stages of each experiment to generate
profiles for all differentially expressed genes in the GOF and
LOF experiments. In Table 1, the number of differentially
regulated genes for every single stage of both experiments is
given. The entire (filtered) gene lists containing unique gene
identifiers and normalized ratio values (log2-transformed) can
be found in Supplementary Tables 1 (GOF) and 2 (LOF).
Potential glial genes were expected to be differentially up-
regulated upon ectopic expression of gcm and downregulated in
the LOF background. Thus, we selected the upregulated genes
of the GOF and downregulated genes of the LOF, respectively,
and listed the genes according to the time point when first
changes in expression appear (see Tables 2 and 3). Candidate
gene selection was done by visual inspection of the differential
regulation profile. The course of differential expression, the
time point when first changes in expression appear, the strength
of differential expression and the comparison between the two
experiments (GOF and LOF) were taken into consideration toselect potential candidate genes. Only few genes showed an
“antagonistic” profile in both experiments (upregulated in GOF
and downregulated in LOF). These were preferentially
analyzed, but the percentage of positive candidate genes
among those turned out to be more or less the same as for the
selection of the two experiments alone. An even more important
step in candidate gene selection was negative selection. We
discarded all those genes from further analysis that showed
differential regulation throughout either experiments without
noteworthy changes or a reverted profile with respect to the
predicted (and observed) profiles of gcm downstream targets.
We also discarded genes that showed differential regulation in
non-adjacent, remote stages, if differential regulation was below
2-fold. All these different filtering criteria were not necessarily
applied at once but rather used in parallel. Both positive and
negative filtering steps reduced the number of potential
candidate genes to about 14% of all differentially regulated
genes. Candidate gene selection was done in three subsequent
rounds, starting with the smallest gene list obtained by the most
stringent filter for reproducibility (min–max separation 0.5).
Database information of the selected genes and results obtained
from our in situ hybridizations was added to the lists. In the LOF
experiment, the positively and negatively tested genes were
scattered throughout the entire gene list (ordered according to
time points of differential regulation) without any apparent
preference. In the GOF, however, clusters of positively and
negatively tested genes appeared. Genes within clusters that
showed an accumulation of positive candidate genes were
preferentially analyzed in subsequent selections. The most
prominent clusters appeared for genes whose upregulation starts
at stages 12 and 13 and lingers for at least one stage. Another
accumulation of positive candidate genes was visible among
those genes with upregulation at stage 16 only. As can be seen
in Table 2, most glial-specific candidate genes of the GOF
experiment were selected from these clusters.
In total, about 400 genes were selected. Literature and
database searches, especially the superb and vastly expanding
Berkeley Drosophila Genome Project's ‘Patterns of gene
expression in Drosophila embryogenesis’ in situ database
(http://www.fruitfly.org/cgi-bin/ex/insitu.pl), were used to get
information about the 400 selected genes. More than 40 were
among our microarray target genes that were already known to
be expressed in glial cells. These genes are marked together with
the source of information in Tables 2 and 3 and in Supplementary
Tables 3 and 4. Another 39 genes were discovered by the two
already published microarray screens for downstream targets of
gcm (Egger et al., 2002; Freeman et al., 2003), which are also
marked in the respective tables. For 300 of the remaining filtered
genes, EST clones or cDNAs were available. These genes were
analyzed by in situ hybridization for their expression in wildtype
as well as in gcmN7-4/gcmN7-4 and Mz1060::gcm backgrounds.
Validation of candidate genes by in situ hybridization
For 300 of the selected differentially regulated genes, Digo-
xygenin-labeled RNA probes were synthesized and hybridized
to wildtype embryos of all developmental stages. Half of these in
Table 1
Statistical analysis of the two time course microarray experiments
GOF Stage 9 Stage 10 Stage 11 Stage 12 Stage 13 Stage 14 Stage 15 Stage 16 Total no. Min–max-
separation
No. of differentially regulated genes (total) 147 167 150 138 96 28 31 34 387 0.5
Upregulated genes (>1.5) 116 149 143 137 84 27 31 28 316 0.5
Downregulated genes (<−1.5) 31 18 7 1 12 1 0 6 71 0.5
No. of differentially regulated genes (total) 596 656 389 346 291 82 80 91 1152 0.2
Upregulated genes (>1.5) 285 447 305 331 263 74 79 74 683 0.2
Downregulated genes (<−1.5) 311 209 84 15 28 8 1 17 470 0.2
No. of differentially regulated genes (total) 877 743 425 395 388 107 107 111 1413 0.0
Upregulated genes (>1.5) 399 496 328 372 322 98 106 89 789 0.0
Downregulated genes (<−1.5) 478 247 97 23 66 9 1 22 625 0.0
LOF Stage 10 Stage 11 Stage 12 Stage 13 Stage 14 Stage 15 Stage 16 Total no. Min–max-
separation
No. of differentially regulated genes (total) 141 135 72 94 44 141 476 0.5
Upregulated genes (>1.5) 80 31 31 50 29 124 273 0.5
Downregulated genes (<−1.5) 61 104 41 44 15 17 205 0.5
No. of differentially regulated genes (total) 414 382 344 319 111 368 1367 0.2
Upregulated genes (>1.5) 243 104 114 169 56 274 744 0.2
Downregulated genes (<−1.5) 171 278 230 150 55 94 658 0.2
No. of differentially regulated genes (total) 598 575 627 632 245 560 2086 0.0
Upregulated genes (>1.5) 353 193 180 269 161 386 1056 0.0
Downregulated genes (<−1.5) 245 382 447 363 84 174 1080 0.0
All data were filtered in M-CHiPS with a constant threshold for differential regulation of 1.5-fold and three different values for reproducibility (min–max separation
0.5, 0.2 and 0.0). Differentially regulated genes were divided into up- and downregulated genes for each stage. The total number of differentially regulated genes
combines all developmental stages analyzed. Since many genes are differentially regulated at more than one stage, the total number given is smaller than the sum of all
stages. Some genes appear both up- and downregulated during the time course of each experiment, especially in the LOF. Hence, total number of differentially
regulated genes is smaller than the sum of up- and downregulated genes.
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genesis. Since we cannot rule out that in these cases the method
did not work, we do not knowwhether these genes are expressed
in the embryo and, thus, they remain uncertain candidates, still.
The other approximately 140 genes showed detectable staining
and were analyzed in more detail (Tables 2, 3, Figs. 3, 4; GOF
and LOF, respectively). In total, 58 genes showed clear expres-
sion in the nervous system, of which 18 genes are exclusively
expressed in glial cells, another 15 genes are expressed in glial
cells together with single neurons, and 22 genes showed a more
ubiquitous staining in the CNS and/or PNS. One gene is
expressed in glial cells together with macrophages, and 7 genes
are expressed in cells of the hematopoietic lineage and macro-
phages alone, which also depend on gcm expression (Bernardoni
et al., 1997; Lebestky et al., 2000; Alfonso and Jones, 2002).
Another 9 genes are expressed in ventral stripes representing
epidermal muscle attachment sites or tendon cells, and one gene
showed expression in glial cells, neurons and tendon cells. gcm
is expressed in tendon cells from stage 12 onwards and is
required for their terminal differentiation (Soustelle et al., 2004).
Another 60 genes are expressed in other tissues and were con-
sidered as negative results. The aim of our microarray approach
was to identify novel genes involved in glial cell differentiation
and to show their dependence on gcm. To test whether the
expression of the newly discovered glial genes is dependent on
gcm, we performed in situ hybridizations in wildtype as well as
in gcm mutant embryos and in embryos with ectopic gcm. The
results of our in situ hybridizations for all tested genes are
included in Supplementary Tables 3 and 4, and all genes thatshowed expression in the CNS as well as in tendon cells and cells
of the hematopoietic lineage are given in Tables 2 and 3.
Expression pattern and profile of novel glial genes
The majority of positive candidate genes from the GOF
experiment showed expression in glial cells and neurons rather
than exclusive expression in glial cells (Table 2). Seven GOF
candidate genes showed expression in glial cells exclusively, of
which four are expressed in many if not all glial cells (CG15860,
CG2893, CG3168, EG:22E5.11) and three are expressed in glial
subsets only (Figs. 3, 5). These are cell body glia (CBG)
(CG6218, CG6783) and peripheral glia (PG) (CG9336). The
GOF resulted in only two genes specifically expressed in tendon
cells (CG9796, CG1153), and no gene expressed in macro-
phages or cells of the hematopoietic lineage. Glial expression of
some of our candidate genes was also shown by Egger et al.
(2002) and Freeman et al. (2003), and some were incorporated
into the BDGP in situ database in the meantime. These genes are
marked in Table 2. As can be seen in Supplementary Tables 3
and 4, many genes with previously described glial expression
showed differential regulation in both of our experiments. These
genes are not shown here as their expression was already des-
cribed elsewhere.
The LOF experiment resulted in a higher number of can-
didate genes with expression in certain glial subtypes and only
two genes with expression in many if not all glial cells (CG2893,
CG3408). Among the glial-subtype-specific expression, we
found genes expressed in cell body glia (CBG) (CG6218,
Table 2
GOF filtered and tested candidate genes
Gene identifiers are given as presented in all Supplementary data. The fold regulation for all examined developmental stages represents the log2-transformed ratio Cy5/Cy3 of median fitted intensities. Values were
obtained from filtering with the M-CHiPS software package (red: upregulation above 1.5-fold; blue: downregulation below 1.5-fold). Expression pattern was confirmed by standard in situ hybridization. Expression in
glial cells (G), in single neurons (N), ubiquitously in the CNS (CNS), and in tendon cells (T) was observed in stages as indicated. Gene expression in Mz1060::gcm (gcm+) and gcmN7-4/gcmN7-4 (gcm−) backgrounds
compared to the wildtypic expression is indicated as increased expression (++), decreased/absent expression (−) or no changes in expression (0). For some of the tested candidate genes, the expression in glial cells
was published during the time of data analysis. The source of information is given in the column titled ‘Lit’. Expression information was either (*B) incorporated into the public in situ database (http://www.fruitfly.
org/cgi-bin/ex/insitu.pl) or published by Egger et al. (2002) (*E) or by Freeman et al. (2003) (*F). GO annotations are presented according to the information given in FlyBase. (For interpretation of the references
to colour in this table legend, the reader is referred to the web version of this article.)
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Table 3
LOF filtered and tested candidate genes
Gene identifiers are given as presented in all Supplementary data. The fold regulation for all examined developmental stages represents the log2-transformed ratio Cy5/Cy3 of median fitted intensities. Values were
obtained from filtering with the M-CHiPS software package (red: upregulation above 1.5-fold; blue: downregulation below 1.5-fold). Expression pattern was confirmed by standard in situ hybridization. Expression
in glial cells (G), in single neurons (N), ubiquitously in the CNS (CNS), in cells of the hematopoietic lineage (H), and in tendon cells (T) was observed in stages as indicated. For further legend and abbreviations,
see Table 2. (For interpretation of the references to colour in this table legend, the reader is referred to the web version of this article.)
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Fig. 3. In situ hybridizations of candidate genes from the GOF experiment in wildtype embryos. Genes and stages are indicated underneath the whole-mount pictures,
shown in a ventral view (left) and a lateral view (right), respectively; anterior is up. If required, different focal sections were combined. Genes are sorted in alphabetic/
numeric order. Examples are shown for genes expressed ubiquitously in the CNS (A, C, E, J, N, O), in single glial cells and neurons (B, F, G, I, L, M), and exclusively
in glial cells (D, H, K).
553B. Altenhein et al. / Developmental Biology 296 (2006) 545–560CG6783), subperineural glia (SPG) (CG5080), longitudinal glia
(LG) (CG11910, CG7433) and peripheral glia (PG) (CG9336,
CG9338). Four of these glial-specific genes were also selected in
the GOF experiment (CG2893, CG6218, CG6783, CG9336).
Seven LOF candidate genes were expressed in tendon cells
(Table 3, Fig. 4), and another eight genes showed expression in
cells of the hematopoietic lineage including macrophages (Table
3, Fig. 4). One additional gene was selected which showed
simultaneous expression in glial cells as well as in macrophages
(CG16876, Table 3, Fig. 4) and one gene with expression in glial
cells and tendon cells (CG15015).
Taken together, 5 genes show expression in nearly all lateral
glial cells, whereas 6 genes show staining in only a subset of
glial cells, like CBG or LG. Additionally, we could identify 7
genes that are expressed in more than one glial subtype, e.g. in
SPG and CBG. Furthermore, 9 genes are expressed in muscle
tendon cells and 8 genes show expression in cells of the hema-
topoietic lineage. In addition, we found one gene simultaneous-
ly expressed in glial cells and in the blood cell lineage and one
gene expressed in muscle tendon cells and in glia. The temporalexpression profiles for most of our candidate genes in wildtype
as well as in both mutant genetic backgrounds (as revealed by in
situ hybridization) resemble the observed differential regulation
in both our microarray experiments at least to some extent.
In order to analyze the expression of our candidate genes in
glial cells in more detail, we performed in situ hybridizations in
combination with anti-Repo antibody stainings. For some of the
genes with exclusive expression in glial cells, the double stain-
ings are shown in Fig. 5. The dependence on gcm was tested by
in situ hybridization in Mz1060::gcm and in gcm mutant back-
grounds. The results are given in Tables 2 and 3. Increased
expression is marked with ‘++’, a decrease in expression is
marked with ‘−’, and no change in expression is markedwith ‘0’.
As expected, all glial-cell-specific genes lack expression in gcm
mutant embryos. Yet, not all of these genes show an increase in
expression upon ectopic activation of gcm. Examples are shown
in Fig. 6.
The temporal expression profile of the selected candidate
genes was determined by in situ hybridization in wildtype
embryos. The results are given in Tables 2 and 3 (expression
Fig. 4. In situ hybridizations of candidate genes from the LOF experiment in wildtype embryos. Genes and stages are indicated underneath the whole-mount pictures
shown in a ventral view (left) and a lateral view (right), respectively; anterior is up. If required, different focal sections were combined. Genes are sorted in alphabetic/
numeric order. Examples are shown for genes expressed ubiquitously in the CNS (B, L), in single glial cells and neurons (A, C, D, F, M, N, O), exclusively in glial cells
(E, G, H, K), as well as in glial cells together with macrophages (J) or tendon cells (I).
554 B. Altenhein et al. / Developmental Biology 296 (2006) 545–560pattern, stage). The first and the last stages of detectable in situ
hybridization signal are indicated. For most of the selected
genes, the expression in wildtype embryos is first detectable at
stage 11 and continues until stage 16. For about 25% of the
positively tested genes, expression was first detected at stage
12 to 13, and two genes are expressed in later stages only
(Tables 2 and 3).
Discussion
Whole genome microarrays have been intensively used over
the last decade. The interpretation of the huge amount of data
generated by such experiments is still critical, but nonetheless
crucial. Many efforts have been taken to standardize chip
design, data acquisition and analysis, but recent papers
demonstrate worrying discrepancies between microarray-de-
rived data (reviewed by Tan et al. (2003); Jordan (2004).
Nevertheless, many papers report on the successful use of
microarrays in various biological systems, ranging from
bacteria to higher organisms, and from single cells to wholeorgans, tissues or individuals. In any way, the DNA chip
technology is highly sensitive and thus susceptible to many
aspects of technical or experimental error. A straightforward
experimental design including quality controls as well as the
determination and reduction of technical (and genetical)
background noise in a given approach and system is a
prerequisite for correct and precise data interpretation.
Improvements in experimental design and candidate gene
selection
The analysis of differential expression along the course of
development and the comparison between gain- and loss-
of-function genetics mark the two major novelties in our
microarray screen for downstream targets of gcm and turned out
to be extremely helpful in selecting potential candidate genes.
The temporal profile of differential expression was used to
either select or discard genes from further analysis. Different
filtering steps enabled us to select potential target genes (about
14% of all differentially regulated genes).
Fig. 5. In situ hybridizations against candidate genes in combination with antibody stainings against the glial protein Repo in wildtype embryos (flat preparations).
Anterior to the left; in A, B, G and I, the midline is at the bottom. A–Gwere stained in the cytoplasm with alkaline phosphatase (in situ hybridization, blue) and nuclear
DAB (anti-Repo, brown). H–I show single confocal stacks of fluorescent in situ hybridizations (magenta) counterstained with anti-Repo antibodies (green).
Expression of genes can be detected in different glial subtypes such as peripheral glia (asterisk), subperineurial glia (arrow head), cell body glia (straight arrow) and
longitudinal glia (bent arrow). CG16876 (BG:DS05899.3) is also expressed in macrophages (black and white dots in panels F and I).
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tially regulated genes were selected and 300 of them were
tested. After validation of these genes by in situ hybridization,
40% were found to be expressed in a gcm-dependent manner,
18% were rated as negative results with expression patterns
outside the CNS/hemocytes/tendon cells, and 42% with no
signal at all, being uncertain candidates, still. For neither of
these we could see any concordance with respect to the
regulation profile, the strength of differential regulation or the
reproducibility. Compared to the microarray screens published
by Egger et al. (2002) and Freeman et al. (2003), the percentage
of positively tested gcm target genes is rather high. The first
published oligonucleotide microarray screen for gcm down-
stream targets (Egger et al., 2002) analyzed the effect of gcm
misexpression induced by scabrous (sca)-Gal4 in stage 11 and
stage 15/16. In this approach, 400 and 1259 differentially
regulated genes were discovered in stages 11 and 15/16, res-
pectively, of which 93 genes overlapped between the two
stages. Taken together, approximately 10% of all genes present
on the oligonucleotide array (with ∼14,000 gene-specific oligo-
nucleotides) appeared to be differentially regulated. Though the
authors could not rule out side-effect-induced differential regu-
lation due to gross morphological abnormalities observed, they
postulate an involvement of the upregulated genes in gliogen-esis or neurogenesis. For none of these newly described poten-
tial gcm target genes the regulation by gcm and the expression in
glial cells was shown in situ. The authors further conceded the
possibility that not all glial genes were necessarily among the
upregulated genes and that a gcm loss-of-function analysis
would be needed to fill these gaps. Comparing our microarray
data with the data presented by Egger et al., we find only minor
overlap. Of the genes published by Egger et al., 30 genes are
differentially expressed in our experiments, too. Half of these
show an opposite behavior (with regard to up-/downregulation),
and only three were selected by our filter criteria and tested
(Table 2). These discrepancies might be due to the different
microarray systems used. Inconsistent results obtained by diffe-
rent microarray systems have been reported (Tan et al., 2003;
Jordan, 2004). However, we believe that the experimental
design (specific Gal4-line, wildtype control, time course, gain-
and loss-of-function) and the resulting possibilities to select
potential target genes are important improvements in our micro-
array approach.
The second published screen for gcm target genes combined
a cDNAmicroarray approach with an in silico prediction of gcm
targets by enhancer/promoter analysis and public in situ hybrid-
ization data (Freeman et al., 2003). Ectopic expression of gcm
was again driven by sca-Gal4, and only stage 12/13 was
Fig. 6. In situ hybridizations of candidate genes in wildtype embryos in comparison to embryos with ectopic activation of gcm (Mz1060::gcm). Flat preparations;
anterior to the left; different focal sections or developmental stages were combined, if required. Longitudinal glial-specific gene expression is not altered upon ectopic
activation of gcm (CG11910 and CG8965, bent arrows in panels A–D), whereas all other glial subtypes can be ectopically induced in Mz1060::gcm (E–L). Shown are
cell body glia (straight arrows in E, G, K) and subperineurial glia (arrow heads in G, I, K). Even restricted expression to single glial cells in wildtype (dorsal
subperineurial glia in CG5080, I) is increased upon ectopic gcm (J).
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Drosophila genes. The authors tested 153 of the upregulated
genes (chosen by strength of differential regulation) of which 18
were proven to be expressed in glial cells, and their upregulation
upon ectopic gcm was confirmed in situ. Though all three
different approaches combined by Freeman and colleagues were
successful and led to a description of 45 novel gcm target genes,
only minor overlap between the three approaches was observed.
The microarray approach itself resulted in the identification of
18 novel target genes representing 12% of the tested genes. The
rather high rate of false positives (88%) was discussed, and the
authors assumed a similar rate for the data presented by Egger
and colleagues. From the 18 microarray-derived gcm target
genes published by Freeman et al., 8 genes were among our
differentially regulated genes. Another 6 candidates of those
identified by the in silico screen for gcm binding sites and 6 of
those found in the in situ database were present in our filtered
gene lists. In total about 45% of all genes described by Freeman
et al. appeared to be differentially regulated in our screen. Most
of them (15 genes) were downregulated in the LOF or even
antagonistically regulated in both experiments.
Novel glial genes
Subsequent filtering and validation steps enabled us to define
clusters of genes with differential glial expression at specifictime points or with specific regulation profiles in both expe-
riments. As can be seen in Tables 2 and 3, most glial-specific
genes in the GOF experiment showed differential regulation in
stage 16, whereas in the LOF the glial-specific genes can be
found throughout all stages. We compared the profiles of diffe-
rential regulation with the temporal expression profiles as
revealed by in situ hybridization in wildtype embryos. Both
profiles do not necessarily match with each other. The regulation
profile in the GOF depends on the Gal4 driver line rather than on
endogenous expression. Hence, the profiles in the LOF experi-
ment show a better overall accordance. Still, the discrepancies
between differential regulation in both experiments and the
endogenous in situ expression pattern cannot be explained.
Astonishingly few genes showed antagonistic regulation in both
experiments. Some of these genes (e.g. CG6218, CG6783)
showed glial expression exclusively. The dependence on gcm
was tested and nicely fits to the obtained microarray data. Most
of the novel glial genes, however, were differentially regulated
in only one of the two experiments. In situ hybridizations were
performed in gcm mutant backgrounds as well as in Mz1060::
gcm embryos, and expression patterns were compared to
wildtype and to the obtained microarray data. With only few
exceptions, most of the novel glial genes discovered from either
experiment showed expression in the respective mutant back-
ground comparable to the observed microarray profiles. Espe-
cially those genes that are also expressed in neurons show an
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significant decrease in gcm mutants. Thus, the lack of glial-
specific downregulation in the LOF experiment is masked by
neuronal expression. Hence, these genes were only selected by
upregulation in the GOF experiment. Conversely, some of the
glial-specific downregulated genes in the LOF experiment are
not differentially upregulated in the GOF. CG11910 for example
does not show an increase in expression in situ upon ectopic
gcm, even though it is expressed exclusively in longitudinal glial
cells (Figs. 6A, B), suggesting that this gene requires factors in
addition to Gcm to be activated. Hence, this gene was not
previously discovered by either of the two gain-of-function
microarray screens (Egger et al., 2002; Freeman et al., 2003).
The same observations were made when analyzing the ex-
pression of CG8965, which is also expressed in longitudinal
glial cells (Figs. 6C, D). Apart from these two, all other genes
with expression restricted to glial subtypes can be activated
ectopically in Mz1060::gcm (Figs. 6E–L). This might correlate
with the origin of the respective glial subtypes, indicating that
spatial, temporal or even other specific cofactors are required for
glial subtype specification. Still, some of the candidate genes of
the LOF experiment were not differentially regulated on
microarrays of the GOF experiment, though in situ hybridiza-
tions show an increase in expression for these genes upon
ectopic activation of gcm in the CNS (e.g. CG11652, BG:
DS05899.3). We cannot explain these discrepancies. Yet, all
these observations demonstrate how carefully microarray expe-
riments need to be designed and analyzed, especially with
respect to the analysis of both gain- and loss-of-function genetics
rather than only one situation.
Functional categories of novel glial genes
We analyzed the composition of the filtered and tested genes
with respect to their gene ontology (GO-annotation) as given in
FlyBase. The GO annotation was used to categorize the putative
or known function into eleven functional classes. Fig. 7 shows
the distribution among these functional categories of all potential
candidate genes (the filtered genes excluding those with nega-
tive in situ hybridizations). These ‘functional categories’ do not
resemble groups of GO annotations of the same hierarchical
level within the genealogic tree of GO annotations, and some
genes might have annotated functions which overlap between
the different categories. Hence, we do not intend to compare
these categories of our filtered genes with those present in the
entire genome, but rather give an overview of the functional
annotations present in our filtered gene lists. For about 25% of
the genes, no GO annotation was given, so their function is
unknown. Signaling-related molecules and proteins involved in
posttranslational protein modification as well as nucleic acid
metabolism are equally distributed, representing 10% of all
potential candidate genes each. Genes from these functional
classes show differential regulation at various developmental
stages examined in either experiments. Among the signaling-
related molecules, the majority are assigned to G-protein-
coupled receptor signaling or small GTPase function. Eighteen
transcription factors (7%) were filtered, whose differential regu-lation starts in early stages (stages 9–12), which is compatible
with a possible function in cell fate specification or early diffe-
rentiation. Another 6% of the filtered genes encode ion trans-
porters, antiporters, symporters or ion channels. Half of these
show differential regulation at late stages only. This also appears
reasonable as homeostatic control is believed to be one of the
functions of glial cells. 13% of all filtered genes have putative
enzymatic function and/or are involved in general metabolism.
Whether this implies glial-specific or experimentally induced
changes in metabolism remains unclear. Most of the filtered
genes with negative in situ hybridization results were among
those with putative metabolic function.
Astonishingly, neither repo nor pnt show differential regu-
lation at any of the examined stages in both of our experiments
and ttk appears downregulated only in the LOF at stage 11.
Similar observations were described by Egger et al. (2002) and
Freeman et al. (2003), where either no upregulation of these gcm
target genes or even downregulation upon ectopic expression of
gcm occurred. With respect to (no) differential regulation of pnt
and ttk, this can be explained by the fact that for both genes
alternative splice variants are expressed in neurons or other cells.
For every gene on our microarray, a single exon was amplified
and spotted. For pnt and ttk, the spotted exons (exons 7 and 5,
respectively) are present in all splice variants. Hence, expression
outside of glial cells may mask the glial-specific expression and
no strong differential regulation is observed. For repo, there is no
such obvious explanation since repo is expressed in all lateral
glial cells exclusively. We extracted the expression values for
repo from all our microarray hybridizations and found a strong
expression of repo throughout the entire time course of both
experiments without notable changes.Moreover, repo appears to
be expressed on our microarrays earlier and stronger than gcm
(already at stage 9), which does not reflect the expression of repo
in vivo. We sequenced the spotted PCR product, and the se-
quence corresponds to exon 1 of the repo gene (as aspired).
Furthermore, we hybridized Northern blots with total RNA from
both wildtype and Mz1060::gcm embryos of different stages
with a repo antisense probe. An increase in repo-mRNA upon
ectopic expression of gcm was clearly detectable (data not
shown). We conclude an unspecific cross-hybridization of
another cDNA to the repo spot. This is obviously one of the
major drawbacks of cDNA microarray approaches.
Further steps towards the understanding of glial cell
development and diversity
A considerable number of genes have already been
identified, which are involved in various aspects of glial cell
biology in the Drosophila embryo: early determining factors
such as gcm, repo and pnt, factors required for terminal glial cell
differentiation and function like loco, EAAT1/2 or moody, and
several genes expressed at various times in between. Most of
these genes are expressed in subsets of glial cells only, and
many are also expressed in other cells or tissues. The biggest
collection of such genes was identified in the screen presented
by Freeman et al. (2003). Our microarray experiments enlarge
this collection and for the first time incorporate results from a
Fig. 7. Functional classification of candidate genes. All filtered (potential) glial genes (255 genes) were grouped into eleven functional categories according to the GO
annotation given in FlyBase. 25% are of unknown function.
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of all these factors with respect to glial cell development,
subtype specification and function, we can group the candidate
genes for example according to (a) time point of expression in
wildtype glial cells, (b) expression pattern in glial subtypes or
(c) their annotated function. Most of the novel glial genes are
expressed from stage 12/13 onwards, and the vast majority is
only expressed in certain cells or subtypes. The primary
determination of the glial cell fate in the embryo is achieved by
Gcm, which is expressed early in development of all lateral glial
cells (Hosoya et al., 1995; Jones et al., 1995; Vincent et al.,
1996). Further subtype specification obviously requires spatial
and/or temporal cofactors. Together, they activate a variety of
other genes, ranging from signaling or transporter molecules to
proteins with putative metabolic function. The restriction of
gene expression to particular glial cells includes all combina-
tions of glial cell classes. Yet, some correlations can be observed
with respect to the classification of glial cells according to
morphological and positional criteria (Ito et al., 1995). Cell
body glia and peripheral glia for example are best confined by
subtype-specific gene expressions. Whether these subtypes
require the respective genes for proper development or function
remains to be shown. Apparently, peripheral glial cells, which
migrate over long distances from their place of origin in the
CNS into the periphery, require precise subtype-specific
regulation. Many of the genes expressed in more than one
subtype are also expressed in subperineurial glial cells. Recent
publications deal with the function of these cells in blood–brain
barrier formation and demonstrate the involvement of one
particular gene, moody (Bainton et al., 2005; Schwabe et al.,
2005). This gene has already been described by Freeman et al.
(CG 4322) and was also found to be differentially regulated in
our screen and filtered by our criteria (EG:22E5.11). moody ispredicted to encode a G-protein-coupled receptor molecule.
The requirement of proper signaling via heterotrimeric G-
protein receptors for glial cell differentiation and formation of
the blood–brain barrier was already proposed earlier (Grand-
erath et al., 1999). One of our newly described glial genes,
CG11910, is also predicted to encode a G-protein-coupled
receptor molecule. It is expressed from stage 14 onwards in
longitudinal glia, a glial cell type that is known to enwrap the
longitudinal axonal connectives. Blood–brain barrier forma-
tion requires the tight connection of subperineurial glial cells
by septate junctions. Some Drosophila genes are known to
regulate the formation of septate junctions, for example,
sinuous or neurexin (Baumgartner et al., 1996; Wu et al.,
2004). Both genes are differentially regulated on our
microarray, too, and the latter is described to be required in
blood–brain barrier formation (Baumgartner et al., 1996).
This suggests that the entire lists of differentially regulated
genes of both our microarray experiments (given in
Supplementary Tables 1 and 2) comprise more glial-specific
candidates, which may be uncovered by further filtering with
respect to certain functional annotations. Yet, the collection of
glial genes identified so far provides an important basis for
the clarification of the genetic network controlling various
aspects of glial development and function.
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